In attendance:  
Paul E. Kinahan, PhD (co-chair)  
Ling X. Shao, PhD (co-chair)  
Richard L. Wahl, MD (co-chair)  
Onikepe Adegbola, MD, PhD  
Keith Allberg  
Ronald Boellaard, PhD  
Andrew Buckler, MS  
Paul Christian  
Patricia Cole, PhD, MD  
Barbara Croft, PhD  
Robert Doot, PhD  
Edward Eikman, MD  
Howard Higley, PhD  
John Hoffman, MD  
Robert Koepppe, PhD  
Lawrence MacDonald, PhD  
Kevin O’Donnell, MASc  
Eric Perlman, MD  
Annette Schmid, PhD  
Anne Smith, PhD  
Rathan Subramaniam, MD  
Daniel C. Sullivan, MD  
John Sunderland, PhD  
Matt Vanderhoek, PhD  
Wenli Wang, PhD  
Wolfgang Weber, MD  
Scott Wollenweber, PhD  
John Wolodzko, PhD  
Jeffrey T. Yap, PhD  
Brian Zimmerman, PhD  
RSNA  
Joe Koudelik  
Julie Lisiecki

Call Summary

Agenda, 2/1
1. Profile Stages description and resolution examples: Mr. Kevin O’Donnell
2. Discussion of ADNI PET studies: Dr. Robert Koepppe
3. Update on PERCIST Validation Project: Dr. Otto Hoekstra
4. EARL FDG-PET/CT Accreditation Program: Dr. Ronald Boellaard
5. Updates on FDG-PET/CT Public comments: Mr. Joe Koudelik / Dr. Eric Perlman
6. Recruitment for multi-site/multi-center, survey: Dr. Richard Wahl
7. Update on QIBA activities: Drs. Kinahan/Shao/Wahl

--

Profile Review Stages Overview: (Mr. O’Donnell)
• The Profile represents the best possible clinical practice, where the goal is to achieve the perfect level of the claim.
• The phases of Profile Review include the following:
  1. Version for public comment
  2. Publicly reviewed version
  3. Technically confirmed version
  4. Clinically confirmed version
• It is important to label Profiles clearly to communicate the stage of maturity or confidence of the Profile so that users can determine its use for their own needs.
• A more detailed document, “QIBA Profile Stages,” has been distributed to the technical committee.
• A link to the Public Comment form is available on the wiki and has been included with call reminders:
• Mr. O’Donnell stressed the importance of providing feedback/suggestions to resolve perceived issues when reviewing the Profile for Public Comment.
• Mr. O’Donnell to send CT Profile version of Public Comment feedback form as reference to Drs. Perlman and Kinahan
• Submitter initials requested if co-chair follow-up in needed (anonymous id “AN-#” also proposed, if needed)

ADNI Project Overview: (Dr. Koepppe)
• Dr. Koepppe provided an overview of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) - ongoing since 2005
• From 2010 – 2016, new subjects to be enrolled
  - Under current procedures, subjects get a baseline scan and two follow-up scan at year intervals
  - 60 sites are represented, with at least 15 scanner models, using different software versions under the FDG-PET umbrella, working to develop standardized scanner protocols across multiple sites
  - Dr. Kinahan to consider polling the technical committee for interest in starting an amyloid effort

EARL Program Update: (Dr. Boellaard)
• This program was a small closed pilot of 10 sites, where quality control (QC) experiments were performed to try to achieve harmonization in the use of SUV in response-assessment studies
• Need for harmonization of resolution-dependent quantitation, rather than minimal performance standards
  o Currently, there are about 60 EANM- accredited sites
  o EANM is also working to reduce the differences among scanners, using multi-center QC and calibration.

Profile – Public Comment – Phase I
• The Profile, FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. v1.02, Version for Public Comment, January 11, 2013, is out for the first phase of Public Comment.
  o Tech committee members are encouraged to add their comments and suggestions for improvement using the form on the QIBA wiki: http://qibawiki.rsna.org/index.php?title=Work_Product_for_Review

Action items for 2/8 – as assigned by the co-chairs:
1. Project update from Dr. Hoekstra on next call
2. Tech Committee members to provide comments on work product for review form (wiki)
3. Tech Ctte members – Please participate in multi-site/multi-center, survey for Dr. Wahl, if possible
4. Mr. O’Donnell to send CT version of Public Comment form as reference to Drs. Perlman and Kinahan

Next call: February 8, 2013 at 9 am CT.